Alymsys (BEVZ92) is produced by mAbxience, a subsidiary of Spanish healthcare firm Insud Pharma (formerly the Chemo Group). BEVZ92 has also been approved in Argentina under the brand name Bevax [1].

Oyavas is produced by German generics giant Stada Arzneimittel (Stada). Stada in-licensed the bevacizumab biosimilar from mAbxience in 2014 [2].

Both Abevmy and Lextemy (MYL-1402O) are produced by US-based Mylan (now Viatris). It has been a long road for the company, which launched Abevmy in India back in November 2017. The company also had the application for its bevacizumab biosimilar accepted by the US Food and Drug Administration (FDA) in February 2020 [3]. However, Mylan’s partner Biocon, announced in December 2020 that the application for MYL-1402O had been delayed. This is due to travel restrictions related to COVID-19 that are preventing inspection of the manufacturing facility, which is required as part of the standard review process.

The CHMP recommended at its meetings held on 25–29 January 2021 and on 22–25 February 2021 that the four bevacizumab biosimilars receive a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.

These recommendations bring the number of bevacizumab biosimilars to be approved in Europe up to 73 [4].

The positive opinion for the bevacizumab biosimilars will now be referred to the European Commission, which grants marketing authorizations for medicines in the European Union.

Related article
Biosimilars of bevacizumab

References
1. GaBI Online - Generics and Biosimilars Initiative. Similar biotherapeutic products approved and marketed in Latin America [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 12]. Available from: www.gabionline.net/Biosimilars/General/Similar-biotherapeutic-products-approved-and-marketed-in-Latin-America 
2. GaBI Online - Generics and Biosimilars Initiative. Stada to in-license adalimumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 12]. Available from: www.gabionline.net/Biosimilars/News/Stada-to-in-license-adalimumab-biosimilar 
3. GaBI Online - Generics and Biosimilars Initiative. FDA accepts application for Mylan’s bevacizumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 12]. Available from: www.gabionline.net/Biosimilars/News/FDA-accepts-application-for-Mylan-s-bevacizumab-biosimilar 
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 12]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.